Bristol Myers says TRIDENT-1 study showed high response rates in lung cancer

Bristol Myers Squibb announced updated results from the registrational TRIDENT-1 study, saying they demonstrated repotrectinib “continued to show high response rates and durable responses” in patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer. In TKI-naive patients with median follow-up of 24.0 months, confirmed objective response rate by Blinded Independent Central Review was 79%, median duration of response and progression-free survival were 34.1 months and 35.7 months, respectively. In patients with measurable brain metastases at baseline, intracranial ORR per BICR was 89% and responses were prolonged. In patients who had been previously treated with one TKI and no chemotherapy (n=56) with median follow-up of 21.5 months, confirmed objective response rate by BICR was 38%, and median DOR and PFS were 14.8 months and 9.0 months, respectively.